Natera is a diagnostics company. Co. operates one segment, the development and commercialization of molecular testing services, applying its proprietary technology in the fields of women's health, oncology and organ health. Co.'s product offerings include: Panorama Non-Invasive Prenatal Test, which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother; Vistara, which is a single-gene mutations screening test performed to identify single-gene disorders; and Horizon Carrier Screening, which determines carrier status for a number of severe genetic diseases that could be passed on to the carrier's children. The NTRA stock yearly return is shown above.
The yearly return on the NTRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NTRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|